Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

57.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axonics Inc

< Previous 1 2 3 Next >
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
Biotech isn't the only place to make money in health care this year. 
Via Investor's Business Daily
Piper Sandler Maintains Overweight Rating for Axonics: Here's What You Need To Know
Piper Sandler has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $82.00 to $84.00. Shares of Axonics are trading down 1.5% over the last 24 hours, at... 
Via Benzinga
Where Axonics Stands With Analysts
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is... 
Via Benzinga
Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance
Via Benzinga
What 9 Analyst Ratings Have To Say About Axonics
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Axonics
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings: 
Via Benzinga
Axonics: Q4 Earnings Insights
Axonics (NASDAQ:AXNX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axonics... 
Via Benzinga
Morgan Stanley Maintains Overweight Rating for Axonics: Here's What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $73.00 to $80.00. Shares of Axonics are trading up 5.7% over the last 24 hours, at... 
Via Benzinga
Recap: Axonics Q2 Earnings
Axonics (NASDAQ:AXNX) reported its Q2 earnings results on Monday, August 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million. 
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Axonics
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the... 
Via Benzinga
Earnings Scheduled For August 1, 2022
Companies Reporting Before The Bell • Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System
The FDA has approved Axonics Inc's (NASDAQ: AXNX) recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). The Axonics F15 recharge-free... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Gain Following Monday's Sell-Off
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled around 800 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
5 Stocks To Watch - Tuesday, Mar. 8
Some of the stocks that may grab investor focus today. 
Via Talk Markets
5 Stocks To Watch For March 8, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects Dick's Sporting Goods, Inc. (NYSE: DKS) to report quarterly earnings at $3.43 per share on... 
Via Benzinga
Analyst Ratings For Axonics
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Axonics Modulation Technologies Inc (AXNX) Q3 2021 Earnings Call Transcript
AXNX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
US Patent Office Rejects Three More Axonics' Challenge To Medtronic Patents
The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed three Medtronic plc (NYSE: MDT) patents related to its InterStim... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.